NCT04123366 2026-04-22
MK-7339-007
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
Merck Sharp & Dohme LLC
Hansoh BioMedical R&D Company
Idience Co., Ltd.
RemeGen Co., Ltd.
Gilead Sciences
BeOne Medicines
Boehringer Ingelheim
Boehringer Ingelheim
Zai Lab (Hong Kong), Ltd.
Mirati Therapeutics Inc.
Pfizer
Genmab
Hoffmann-La Roche
Hoffmann-La Roche
Nanolattix Biotechnology Co., Ltd.
Boehringer Ingelheim
RenovoRx